BI Nutraceuticals Extends Ingredient Sourcing Reach To Build Customer Base
This article was originally published in The Tan Sheet
With a manufacturing plant in China, an expanding portfolio of ingredients and significant investments in quality control, BI Nutraceuticals believes it is positioned to grow in a post-GMP world
You may also be interested in...
The Carlyle Group's planned acquisition of NBTY for $3.8 billion may not be the only private equity offer to surface for the dietary supplement giant
Vasilios "Bill" Frankos, former director of FDA's Division of Dietary Supplement Programs, left his mark on the industry after shepherding the supplement good manufacturing practices final rule from development to publication and through implementation
FDA's final rule for dietary supplement good manufacturing practices completed its phase-in for the industry June 25, and the agency now prepares to conduct inspections of small firms, which have struggled the most to comply with the regulation